Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples